Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw these advertisements and seeks damages from Lilly.

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…

The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.

Den danske legemiddelprodusenten hevder Eli Lilly villeder forbrukere i sin markedsføring.

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says…

Novo Nordisk mener, at Eli Lilly har benyttet sig af vildledende markedsføring i USA og går nu rettens vej.

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its…

"Through this action, Novo Nordisk is seeking a permanent injunction requiring Lilly to pull its misleading comparative advertising across all platforms... "

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing…

Im Milliardenmarkt für Abnehmspritzen verklagt der dänische Pharmakonzern seinen US-Rivalen: Dessen Werbung täusche Verbraucher mit veralteten Vergleichen, so der Vorwurf.

Le duel entre les leaders du marché de l'anti-obésité se poursuit devant les tribunaux américains. Le fabricant du Wegovy a saisi la justice, estimant que les publicités pour…

Novo Nordisk has accused rival Eli Lilly of runnin | Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public…

Das dänische Unternehmen sieht sich in einer Werbung seines US-Konkurrenten falsch dargestellt und klagt. Worum es in den Streit geht.

La casa farmaceutica danese accusa la rivale americana di aver promosso Zepbound e Mounjaro con confronti «falsi e fuorvianti» rispetto a Wegovy e Ozempic. Nel mirino una campagna…

La compañía danesa critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense, Mounjaro y Zepbound

Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.

Novo Nordisk, the maker of Wegovy, has filed a lawsuit on Tuesday against competitor Eli Lilly alleging that its GLP-1 advertisements are misleading.

La farmacéutica danesa acusa a su competidora estadounidense de comparar la eficacia de sus medicamentos en su dosis más alta con una menor de Wegovy y Ozempic

Novo Nordisk cita in giudizio Eli Lilly: sotto accusa campagne basate su dati superati per esagerare l'efficacia dei farmaci GLP-1

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.